<DOC>
	<DOCNO>NCT01499108</DOCNO>
	<brief_summary>Background : Preclinical blood pressure ( BP ) data study hypoglycemic effect liraglutide treatment ( LEAD program ) , reveal significant antihypertensive potential . The time course mechanism behind effect unknown . Objectives : To evaluate time course antihypertensive effect liraglutide treatment patient type 2 diabetes Design : Open-label study intervention subsequent washout period Patient Population : 35 hypertensive ( SBP ≥130 mm Hg DBP ≥80 mmHg ) patient type 2 diabetes . Intervention : All patient treat liraglutide 0.6 mg daily 7 day titrate 1.2 mg daily 14 day titrate 1.8 mg daily 4 week . This follow washout period 3 week without liraglutide treatment . Endpoints : 24-hour blood pressure , natriuresis , extra cellular volume ( ECV</brief_summary>
	<brief_title>Time Course Blood Pressure Lowering Effect Liraglutide Therapy Type 2 Diabetes</brief_title>
	<detailed_description>Hypotheses Primary hypothesis • Liraglutide treatment cause reduction 24h BP Secondary hypothesis : - The effect BP may mediate increase natriuresis , thereby affect ECV - The effect BP may mediate decrease arterial stiffness central aortic pressure Purpose Primary purpose • To assess quickly antihypertensive effect liraglutide treatment set initiation patient type 2 diabetes Secondary objective - To measure effect liraglutide treatment natriuresis . - To measure effect liraglutide treatment ECV - To measure effect liraglutide treatment arterial stiffness - To measure weight change initiation liraglutide treatment</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Must give write informed consent participation . Patient information consent form must approve Danish Medicines Agency Regional Scientific Ethical Committee 2 . Male female patient &gt; 18 year type 2 diabetes ( WHO criteria ) . 3 . Patients must treatment metformin . Any form treatment SU compound discontinue washed two week prior start study drug . 4. eGFR ≥ 60 ml/min/1.73 m2 ( estimate MDRD formula ) 5 . Fertile female patient must use chemical , hormonal mechanical contraceptive menopause ( i.e . must regular menstrual bleeding least one year ) undergone bilateral oophorectomy surgically sterilize hysterectomised least six month prior screen 6 . Patients must antihypertensive treatment elevate blood pressure ( SBP ≥130 mm Hg DBP ≥80 mmHg ) , low 170/105 mm Hg baseline patient must stable antihypertensive medication least 4 week prior baseline 7 . Patients must stable hypoglycemic medication least two week first visit . 8 . Must able communicate investigator 1 . Ongoing insulin therapy 2 . BP &gt; 170/105 mm Hg baseline 3 . Type 1 diabetes mellitus 4 . Chronic pancreatitis / previous acute pancreatitis 5 . Known suspected hypersensitivity trial product ( ) relate product . 6 . Treatment oral glucocorticoid , calcineurin inhibitor , dipeptidyl peptidase 4 ( DPP4 ) inhibitor Investigator 's opinion could interfere glucose lipid metabolism 90 day prior screen 7 . Cancer ( except basal cell skin cancer squamous cell skin cancer ) clinically significant disorder , except condition associate type 2 diabetes history , investigator opinion could interfere result trial 8 . Inflammatory bowel disease 9 . Cardiac disease define : Decompensated heart failure ( NYHA class IIIIV ) and/or diagnosis unstable angina pectoris and/or myocardial infarction within last 6 month 10 . Previous bowel resection 11 . Body mass index &lt; 18.5 kg/m2 12 . Females childbearing potential pregnant , breastfeeding , intend become pregnant use adequate contraceptive method 13 . Clinical sign diabetic gastroparesis 14 . Impaired liver function ( transaminase &gt; two time upper reference level )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>hypertension</keyword>
	<keyword>liraglutide</keyword>
	<keyword>kidney function</keyword>
</DOC>